Keywords direct-acting antiviral, drug-drug interaction, hepatitis C, management Several direct-acting antiviral agents (DAAs) have marketing authorization in Europe and in the USA and have changed the landscape of hepatitis C treatment: each DAA has its own metabolism and drug-drug interactions (DDIs), and managing them is a challenge. To compile the pharmacokinetics and DDI data of the new DAA and to provide a guide for management of DDI. An indexed MEDLINE search was conducted using the keywords: DAA, hepatitis C, simeprevir, daclatasvir, ledipasvir, sofosbuvir, 3D regimen (paritaprevir/ritonavir, ombitasvir, dasabuvir), DDI and pharmacokinetics. Data were also collected from hepatology, and infectious disease and clinical pharmacology conferences abstracts. Food can play a role in the absorption of DAAs. Most of the interactions are linked to metabolism (cytochrome P450-3 A4 [CYP3A4]) or hepatic and/or intestinal transporters (organic anion-transporting polypeptide and P-glycoprotein [P-gp]). To a lesser extent other pathways can be involved such as breast cancer resistance protein transporter or UDP-glucuronosyltransferase metabolism. DDI are more likely to occur with 3D regimen, daclatasvir, simeprevir and ledipasvir, as they are all both substrates and inhibitors of P-gp and/or CYP3A4, than with sofosbuvir. They can increase concentrations of coadministered drugs and their concentrations may be influenced by P-gp or CYP3A4 inducers or inhibitors. Overdosage or low dosage can be encountered with potent inducers or inhibitors of CYP3A4 or drugs with a narrow therapeutic range. The key to interpret DDI data is a good understanding of the pharmacokinetic profiles of the drugs involved. Their ability to inhibit CYP450-3A4 and transporters (hepatic and/or intestinal) can have significant clinical consequences.
Background
The emergence of direct-acting antiviral agents (DAAs) represents a major advance in hepatitis C virus (HCV) infection treatment. New DAAs include: new NS3 protease inhibitor simeprevir and paritaprevir boosted by ritonavir; the NS5A inhibitors daclatasvir, ledipasvir and ombitasvir; and the nucleotide NS5B polymerase inhibitors sofosbuvir and dasabuvir. They are approved in an interferon-free regimen, with or without ribavirin [4, 5] and can cure 80-90% of patients [6, 7] . Although highly effective and well tolerated, each DAA has its own metabolism and presents an important potential for drug-drug interactions (DDI). The most common metabolic pathways leading to DDI include CYP450, drug uptake transporters such as organic anion transporting polypeptide, and drug efflux transporters such as P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). DAAs can act as substrates, inhibitors and/or inducers of metabolic enzymes, and transporters, so they can increase toxicity or decrease effectiveness of coadministrated drugs and vice versa [8, 9] . Comedications can influence the choice of a DAA. In clinical practice, non-HCV medications that have the potential for interactions with HCV treatments are frequently prescribed to patients with chronic HCV infection [10, 11] .
Understanding pharmacokinetic mechanisms is an essential prerequisite to manage DDI [12] . In this review we summarise pharmacokinetics and DDI with new DAA agents against hepatitis C: simeprevir, daclatasvir, ledipasvir/sofosbuvir and 3D regimen, with a view to help clinicians manage DDI issues.
Methods
Only articles, abstracts and posters in English were selected. An indexed MEDLINE search was conducted concurrently from January 2007 until December 2015 by the medical head of hepatology department and a clinical pharmacist, using the keywords:
"simeprevir", "daclatasvir", "ledipasvir", "sofosbuvir", "paritaprevir", "ombitasvir", "dasabuvir", "direct-acting antiviral", "hepatitis C", "hepatitis C treatment", <AND > "drug-drug interactions" or <AND > "pharmacokinetic". Randomised clinical trials, in vitro studies, prospective and retrospective human studies both in HCV infected patients and in healthy subjects, literature reviews, and expert clinician opinion papers were included. We collected all reviews and articles that summarised DDI for DAA.
Articles were first reviewed based on title and abstract (n = 134) and secondly on full text (n = 61). We excluded: the first generation protease inhibitors telaprevir and boceprevir as they are no longer used; new DAA that were still in clinical trials in Europe in 2015; DAAs that were discontinued; and articles on DDI simulations.
To complete the data, the two reviewers collected abstracts from hepatology, infectious diseases and clinical pharmacology meetings. Meetings selected were the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), the Annual Meeting of the European Association for the Study of the Liver (EASL), HEPDART, The Annual Conference on Retroviruses and Opportunistic Infections (CROI), the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), and The International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy. Each meeting was screened to find all abstracts or posters regarding DAA and DDI and pharmacokinetics (n = 53). European summaries of product characteristics were also included (n = 5).
Results
All the factors that influence DAA pharmacokinetics are summarised in Table 1 . 
Food effect
No [16] No [16] Take with food [13] No [23] Take with food [19]
Hepatic impairment
No dose adjustment for patients with mild, moderate or severe hepatic impairment [104] No dose adjustment for patients with mild, moderate or severe hepatic impairment [105] - QT Avoid with amiodarone or other bradycardia treatment [37] Avoid with amiodarone or other bradycardia treatment [37] Avoid with amiodarone or other bradycardia treatment [22] Food effects and absorption
Food increased the area under the curve (AUC) of simeprevir by 61% after a high-fat, high-calorie breakfast, so simeprevir is best taken with food [13] . Sofosbuvir is a prodrug that is converted to GS-461 203, an active metabolite, and GS-331 007, its predominant metabolite which represents >90% of the exposure [14, 15] . As he exposure to GS-331 007 was not altered in the presence of a high-fat meal, sofosbuvir can be taken with or without food [16] .
Ledipasvir exhibits pH-dependent solubility but studies showed that AUC of ledipasvir and sofosbuvir were not significantly changed by H 2 -receptor antagonists (famotidine) or omeprazole 20 mg if it is taken simultaneously. However, if omeprazole 20 mg was taken 2 h before ledipasvir, exposure to ledipasvir was decreased by 50% (Table 2) [16] . As others dosages were not tested, ledipasvir should preferably not be taken with proton pump inhibitors [17] . The administration of ledipasvir/sofosbuvir with a meal did not alter ledipasvir AUC or C max [16] so ledipasvir/sofosbuvir can be taken with or without food.
Daclatasvir C max and AUC were reduced by 28% and 23%, respectively with a high-fat meal but this reduction was not considered clinically significant [18]. Paritaprevir is combined with ritonavir and ombitasvir in a tablet coat. Food increased the exposure (AUC) of 2D regimen by up to 82%, 211% and 49%, respectively relative to the fasting state, so the combination of these drugs should be taken with food [19, 20] .
Food increased the AUC of dasabuvir by up to 30% compared to fasting. It is therefore recommended to take dasabuvir with food [19] .
Distribution
Daclatasvir, simeprevir, ledipasvir and 3D regimen extensively bind to plasma proteins (> 98%), [19, [21] [22] [23] . Sofosbuvir is 85% bound to human plasma proteins, whereas protein binding of GS-331 007 is very low [21] . Contrary to preconceived ideas, the concentration increase linked to competitive binding to plasma proteins rarely has any clinical impact [24] , as kinetic interactions initially attributed to a protein displacement are actually explained by metabolic inhibition or by renal transport inhibition [24] .
Effect of transporters P-pg. Drugs in enterocytes can be excreted back into the gut lumen by efflux transporters such as P-gp ( Figure 1 ). P-gp can limit drug absorption [25] . In the liver, P-gp is a main transport protein on the bile canalicular membrane responsible for biliary excretion of drug metabolites [26, 27] . Sofosbuvir and ombitasvir are substrate of P-gp [14] . Paritaprevir, ritonavir, dasabuvir, ledipasvir, daclatasvir and simeprevir are substrates and inhibitors of P-gp [18, 19, 21, 28, 29] (Table 1) .
Coadministration of a P-gp inhibitor (e.g. simeprevir, ledipasvir or daclatasvir) with a P-gp drug substrate will block P-gp's action and thus increases substrate absorption. Coadministration of a P-gp inducer (i.e. rifampicin) with a P-gp substrate results in a substrate concentration decrease. Thus rifampicin, when administered with ledipasvir/sofosbuvir, led to a 72% and 59% decrease in sofosbuvir and ledipasvir AUC, respectively [30, 31] . P-gp potent inducers should not be used with daclatasvir, ledipasvir/sofosbuvir or 3D regimen. In healthy subjects, administration of digoxin (a P-gp substrate) with simeprevir or daclatasvir or ledipasvir or paritaprevir/ritonavir/ombitasvir (P-gp inhibitors) led to a digoxin AUC increase of 39%, 27%, 34% and 36% AUC respectively [18, 30, 32, 33] . Digoxin should thus be initiated at a lower dosage and be monitored.
P-gp substrates are often also cytochrome P450 (CYP450) substrates, which make P-gp interactions most often negligible when compared with cytochrome interactions [25] . It should be noted, however, that a few drugs are exclusively P-gp substrates, such as digoxin, and some nucleotide and nucleoside reverse transcriptase inhibitors (NRTI) [34] .
Organic anion-transporting polypeptide. The organic aniontransporting polypeptide 1B1 (OATP1B1) transporter at the sinusoidal pole of the hepatocyte is an influx transporter ( Figure 1 ). This transporter is involved in the hepatic influx of some drugs such as statins (pravastatin, rosuvastatin) [35] . Simeprevir, daclatasvir, ledipasvir, paritaprevir and ritonavir are all substrates and inhibitors of the OATP1B1 transporter, whereas sofosbuvir, ombitasvir and dasabuvir
Figure 1
Transporters involved in drug-drug interaction of new DAAs are not substrates [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . In healthy subjects, administration of a single dose of rosuvastatin with simeprevir or daclatasvir at 60 mg once daily or 3D regimen results in a respectively AUC increase by 181%, 58% and 159%, by blocking their hepatic uptake [18, 28, 33] . The dose of rosuvastatin should be decreased when coadministrated with simeprevir or daclatasvir, and should not exceed 5 mg with 3D regimen. Tolerance should be monitored [19, 28, 33] . With 3D regimen pravastatin dose should be reduced by 50% [19, 33] .
BCRP. BCRP (ABCG2) limits intestinal absorption of lowpermeability substrate drugs and mediates biliary excretion of drugs and metabolites. Many drugs were identified as substrates (e.g. sulfasalazine, rosuvastatine) or inhibitors of BCRP (e.g. curcumin, lapatinib) in vitro [36] , yet clinical DDIs attributed directly and specifically to BCRP are limited due to overlap with other transporters, as well as metabolic pathways. Sofosbuvir is a substrate of BCRP whereas GS-331 007 is not [37] . Ombitasvir and simeprevir are substrates of BCRP [19] . Paritaprevir, simeprevir, ritonavir, dasabuvir, ledipasvir and daclatasvir are inhibitors of BCRP [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] . However, sulfasalazine, curcumin, lapatinib have not been studied with any of DAAs. Only rosuvastatin was tested with daclatasvir, simeprevir and 3D regimen but the increase of rosuvastatin AUC could be also due to OATP inhibition [33] .
Metabolism
Biotransformation very often involves isoenzymes of the cytochrome P450 superfamily especially the isoenzyme cytochrome P450-3 A4 (CYP3A4). A drug with a narrow therapeutic range (immunosuppressants for example) can give rise to a clinically significant interaction more readily than a drug with a wide therapeutic range [38] .
Effects of DAAs on CYP3A4 substrates. Sofosbuvir and ledipasvir are not metabolised by CYP3A4 [37] . Ledipasvir is slowly metabolised via an unknown mechanism [21] (Table 1 ). Sofosbuvir and ledipasvir have been tested in healthy volunteers with cyclosporine, tacrolimus, methadone, ethinyl oestradiol, all substrates of CYP3A4, without clinically significant interactions as expected (Tables 3-5) [28, 39, 42] . Several studies have Table 3 Drug-drug interactions between immunosuppressants and direct-acting antiviral agents (DAAs) [47]
↔, no clinical change (< 25%); ↑, increase in AUC; ↓, decrease in AUC AUC, area under the curve; HCV, hepatitis C virus [99]
No dose adjustment.
[33] [21]
Simeprevir Not tested Expected: simeprevir↓ (strong induction of CYP3A4)
Not recommended. Loss of therapeutic effect of simeprevir.
[22]
Sofosbuvir Not tested Expected: ↓ sofosbuvir AUC ↓ GS-331 007
Not recommended. Loss of therapeutic effect of ledipasvir.
[37]
3D regimen Healthy subjects
↔, no clinical change (< 25%); ↑, increase in AUC; ↓, decrease in AUC AUC, area under the curve; HCV, hepatitis C virus; NA, not applicable Table 5 Drug-drug interactions between contraceptives and direct-acting antiviral agents (DAAs) Clinical monitoring is recommended.
[21]
Simeprevir Not tested Expected ↑ dabigatran (inhibition of P-gp)
Safety monitoring is advised when initiating.
[ The lowest dose of digoxin should be initially prescribed. Serum digoxin concentrations should be monitored.
[23]
(continues) tested sofosbuvir and ledipasvir in post-transplant patients and no interaction with any concomitant immunosuppressive agent was reported [43, 44] . German et al. suggest that sofosbuvir with ledipasvir could be administered with cyclosporine or tacrolimus [30, 45] .
Paritaprevir, ombitasvir and dasabuvir are substrates of CYP3A4 [19] . Paritaprevir is an inhibitor of CYP3A4 and ritonavir is used as a booster in 3D regimen because it is a strong inhibitor of CYP3A4 that leads to increased bioavailability of paritaprevir [20] . Ritonavir of the 3D regimen increases human immunodeficiency virus (HIV) protease inhibitors exposure, which is why the recommended dose of darunavir is 800 mg once daily and the recommended dose of atazanavir is 300 mg once daily, without ritonavir, when administered with 3D regimen [46] . 3D regimen with substrates of CYP3A4 could increase coadministered drug exposition. A phase 1 study demonstrated a three-fold increase in cyclosporine half-life and seven-fold increase in tacrolimus half-life when administered concomitantly with 3D regimen [47] . Therefore, in liver transplant recipients with recurrent HCV genotype 1 infection on stable cyclosporine or tacrolimus therapy, cyclosporine was reduced to 20% of the usual daily dose given once daily, while tacrolimus was reduced to either 0.5 mg once weekly or 0.2 mg every 3 days [48] . Dick et al. recommend empirically close monitoring, 2-3 times a week when 3D regimen is used with immunosuppressive agents [49] . Simeprevir is a substrate and mild inhibitor of CYP3A4 in the intestine by increasing midazolam AUC by 45% when administered orally and C max by 31%, [32] (Table 4) [50] . In healthy volunteers, administration of single atorvastatin dose at 40 mg or simvastatin at 40 mg with simeprevir increases atorvastatin AUC by 110% and simvastatin AUC by 50%, probably via inhibition of CYP3A and OATP by simeprevir [32] (Table 6) .
Sometimes, interactions are not as expected. For example, simeprevir with single-dose tacrolimus at 2 mg resulted in a 17% decrease in tacrolimus AUC compared with tacrolimus administered alone [51] . With cyclosporine, simeprevir increased cyclosporine AUC by 19%, which was not considered clinically relevant [51] . However, therapeutic drug monitoring is recommended [52] . These results were confirmed in the SATURN study [28, 53] but cyclosporine increased simeprevir exposure AUC by 481% so the coadministration is now contraindicated (Table 3) . Apart from this result, new DAAs in liver transplanted patients have a good safety profile [54] [55] [56] [57] [58] .
Daclatasvir is a CYP3A4 substrate [19, 23] . Tacrolimus and cyclosporin were unaffected by concomitant administration of multiple doses of daclatasvir [59, 60] . Studies conducted in liver-transplanted patients treated with tacrolimus or everolimus or cyclosporine confirms that the coadministration of sofosbuvir and daclatasvir is safe and efficient in these patients. [61] [62] [63] .
Effects of DAAs on other CYP substrates. Simeprevir and daclatasvir have no clinically relevant effects on CYP2C9, 2C19 and 2D6 [50] as confirmed by their nonsignificant effect when coadministrated with escitalopram, dextrometorphan (substrates of CYP2D6) [32, 64] , omeprazole (substrate of CYP2C19) and warfarin (substrate of CYP2C9) [32] .
Ritonavir could induce CYP2C19 [65] . When omeprazole 40 mg once daily was coadministered with the 3D regimen in healthy volunteers, omeprazole AUC decreased by 38% due to ritonavir induction on CYP2C19, so it is recommended to monitor patients for decreased efficacy of all proton pump inhibitors [33] (Table 2 ). However, with sulfamethoxazole (substrate of CYP2C19) and trimethoprim, no dose adjustment is required [66] .
The 3D regimen did not affect the exposures of the CYP2C9 substrates (such as warfarin) or the CYP1A2 substrates (such as theophylline and caffeine) or CYP2D6 substrates (such as duloxetine, desipramine). Therefore, these drugs are not expected to require dose adjustments [67] . Caution is advised.
[32]
↔, no clinical change (< 25%); ↑, increase in AUC; ↓, decrease in AUC AUC, area under the curve; NA, not applicable; P-gp, P-glycoprotein Table 8 Drug-drug interactions between direct-acting antiviral agents (DAAs) and antiretrovirals [ [50]
Sofosbuvir Not tested ↔ Not expected. [69]
Sofosbuvir Not tested
No data.
Tenofovir/ emtricitabine 3d regimen ↔ ombitasvir ↔ paritaprevir with dasabuvir: ↔ paritaprevir without dasabuvir:
[46]
Abacavir/ lamivudine [69, 70] . An extrapolated daclatasvir dose of 90 mg with efavirenz is estimated to provide exposure similar to daclatasvir at 60 mg daily alone [71] and simeprevir and efavirenz should not be associated. Efavirenz with 3D regimen resulted in alanine aminotransferase elevations and early discontinuation of the study. The association is contraindicated [72] .
As expected, coadministration of sofosbuvir/ledipasvir and efavirenz did not induce a clinically significant effect on ledipasvir and sofosbuvir AUC [29, 73] .
Strong inhibitors of CYP3A4 may increase the plasma levels of daclatasvir, simeprevir and 3D regimen. In healthy volunteers, erythromycin and simeprevir association increased AUC simeprevir by 647% and AUC erythromycin by 90%. [32] . Ritonavir with simeprevir increases simeprevir AUC by 618% respectively [47, 70] . Thus coadministration of simeprevir with any protease inhibitor is not recommended. Ketoconazole at 400 mg once a day with daclatasvir or 3D regimen increases daclatasvir AUC by 200% [18], paritaprevir AUC by 100%, ritonavir AUC by 57%, and dasabuvir AUC by 42% [74] . The dose of daclatasvir should be decreased to 30 mg once daily if coadministered with ketoconazole and 3D regimen is contraindicated with all antifungal azoles (Table 7) .
Daclatasvir, simeprevir or paritaprevir coadministration with cyclosporine (a CYP3A4 inhibitor) resulted in daclatasvir, simeprevir and paritaprevir AUC increase (40%, 481% and 72%) [19, 53, 59] . No dose adjustment of antiviral is required except for simeprevir, coadministration of which is contraindicated [45, 49, 75] .
Dasabuvir is a substrate of CYP2C8: in the presence of gemfibrozil (CYP2C8 inhibitor), dasabuvir AUC increased by 1030%, so gemfibrozil is contraindicated with 3D regimen [19] .
Other drugs were tested with simeprevir, sofosbuvir, ledipasvir, daclatasvir and 3D regimen [76] [77] [78] [79] [80] [81] [82] : data available are appended in supporting information (Tables S1, S2 , S3, S4, S5 published online). Treatment with daclatasvir, simeprevir, sofosbuvir/ledipasvir is associated with a low potential for serious DDI. However, moderate DDI are frequent and have to be considered [73, 83] . Polepally et al. have studied the effects of more than 120 comedications with the 3D regimen. Despite of an apparent effect on paritaprevir exposure, no dose adjustment of 3D regimen was necessary [80, 81] . In HIV-coinfected patients, addition of sofosbuvircontaining therapy is associated with a lower DDI prevalence than a simeprevir-containing therapy [86, 87] (Table 8) . Sofosbuvir and daclatasvir are ideally suited for HCV/HIV-coinfected patients, whereas simeprevir with sofosbuvir is recommended for HCV-monoinfected patients [88] [89] [90] [91] . 3D regimen has a highest potential of DDI and comedication should be analysed carefully before initiating HCV treatment [87, 92] .
Other factors influencing the metabolism of DAAs: UGTA1 enzyme. UDP-glucuronosyltransferase (UGT) enzymes catalyse the conjugation of endogenous substances such as bilirubin and exogenous drugs. Sofosbuvir, ledipasvir, simeprevir and daclatasvir were tested with raltegravir, whose metabolism depends on UGTA1 enzyme: no clinically significant pharmacokinetic changes were observed, and no dose adjustments are needed [42, 69, 73, 93] . Paritaprevir, ombitasvir and dasabuvir are inhibitors of UGT1A1 so coadministration with raltegravir increase raltegravir AUC by 134%. 3D regimen is contraindicated with norgestimate/ethynylestradiol because of an increase of norgestrel and norgestromine by 164 and 160% respectively [33] .
Elimination
Only competition in the urinary excretion of a drug causes a risk of clinically significant DDI. Elimination of simeprevir, ledipasvir daclatasvir and 3D regimen occurs mainly via biliary excretion. Sofosbuvir is eliminated at the rate of approximately 80%, 14% and 2.5% in urine, faeces and expired air, respectively [37] . Most of the sofosbuvir dose recovered in urine was GS-331 007 (78%). As GS-331 007 is an inactive metabolite, a competition with another drug mainly eliminated by the kidneys could lead to an overdosage of sofosbuvir [94] . A small study in HCV patients with severe renal impairment showed that low dose of sofosbuvir (200 mg) with ribavirin at 200 mg once daily resulted in comparable sofosbuvir and approximately four-fold higher GS-331 007 exposures compared with sofosbuvir at 400 mg. The treatment was safe and well-tolerated [95, 96] .
Conclusion
DDIs can occur at several steps during drug metabolism. Food can play a role in the absorption of DAAs. Transporters and cytochromes are mainly responsible for clinically significant interactions. Sofosbuvir is less prone to DDIs, because its metabolism does not depend on cytochromes. Online tools can be helpful, but clinicians should also run a checklist of key questions before beginning a HCV treatment, such as:
• Does the liver metabolise the coadministered drug? If so, are they substrates inhibitors or inducers of P-gp, OATP or CYP3A4 or other transporters? • Is the patient taking drugs with a narrow therapeutic range?
Is it possible to monitor the drug? • Should a substitution be considered? How?
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